Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun 13;40(6):603-605.
doi: 10.1016/j.ccell.2022.05.010. Epub 2022 Jun 2.

When immunotherapy meets surgery in non-small cell lung cancer

Roy S Herbst  1 , Meina Wang  2 , Lieping Chen  3
Affiliations
Free article
Comment

When immunotherapy meets surgery in non-small cell lung cancer

Roy S Herbst et al. Cancer Cell. .
Free article

Abstract

The results of the most recent Checkmate-816 trial in The New England Journal of Medicine using combination neoadjuvant immunotherapy with platinum-based chemotherapy in resectable non-small cell lung cancer demonstrate the effectiveness of neoadjuvant immunotherapy and provide further support that biology and personalized therapy represent the foundation of lung cancer treatment.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests R.S.H. receives consulting fees from Abbvie Pharmaceuticals; ARMO Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Bolt Biotherapeutics; Bristol-Myers Squibb; Candel Therapeutics, Inc.; Cybrexa Therapeutics; eFFECTOR Therapeutics, Inc.; Eli Lilly and Company; EMD Serono; Foundation Medicine, Inc.; Genentech/Roche; Genmab; Gilead; Halozyme Therapeutics; Heat Biologics; I-Mab Biopharma; Immunocore; Infinity Pharmaceuticals; Loxo Oncology; Merck and Company; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Ocean Biomedical, Inc.; Oncternal Therapeutics; Pfizer; Refactor Health, Inc.,; Ribbon Therapeutics; Sanofi; Seattle Genetics; Shire PLC; Spectrum Pharmaceuticals; STCubePharmaceuticals, Inc; Symphogen; Takeda; Tesaro; Tocagen; Ventana Medical Systems, Inc.; WindMIL Therapeutics; and Xencor, Inc.; receives research support from AstraZeneca; Eli Lilly and Company; Genentech/Roche; and Merck and Company; and serves as a board member (non-executive/independent) for Immunocore Holdings Limited and Junshi Pharmaceuticals. L.C. serves on the scientific advisory board/board of directors of NextCure, Zai Lab, Pfizer, Vcanbio, Junshi, GenomiCare, and Tayu and has sponsored research funds from Normunity and DynamiCure. M.W. declares no competing interest.

Comment on

  • Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
    Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Forde PM, et al. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. N Engl J Med. 2022. PMID: 35403841 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources